CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eisai Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eisai Co Ltd
Eisai Main Bldg., 4-6-10, Koishikawa
Phone: +81 338173700p:+81 338173700 BUNKYO-KU, TKY  112-8088  Japan Ticker: 45234523
Business Summary
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board of Directors, Independent Director FumihikoIke 72 6/1/2023 6/1/2021
Chief Executive Officer, Representative Executive Officer, Director HaruoNaito 76 6/1/2014 6/1/1983
Executive Officer, Chief Financial Officer MitsuruShomon 52 6/14/2024 4/1/2023
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MGi Pharma, Inc. SUITE 100, 5775 WEST OLD SHAKOPEE RD BLOOMINGTON MN United States
Eisai Inc. 100 Tice Blvd. Woodcliff Lake NJ United States
Morphotek Inc. 210 Welsh Pool Rd Exton PA United States

Business Names
Business Name
4523
Bracco-Eisai Co., Ltd.
Clinical Supply Co., Ltd.
47 additional Business Names available in full report.

General Information
Number of Employees: 11,067 (As of 3/31/2024)
Outstanding Shares: 282,282,262 (As of 9/30/2024)
Shareholders: 89,333
Stock Exchange: TYO
Fax Number: +81 338113305


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024